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Purpose: The short and long-term anatomic results of percutaneous transluminal renal 
angioplasty (PTRA) in the treatment of atherosderotic renovascular disease have been 
poorly documented because of a lack of follow-up arteriography. The purpose of this 
study was to evaluate the anatomic results of PTRA with serial duplex examinations. 
Methods: The records of 41 patients who underwent 52 primary PTRA procedures and 
had subsequent duplex follow-up of at least 6 months were reviewed. After PTRA, renal 
arteries were classified as normal, <60% stenosis, -->60% stenosis, or occluded on the basis 
of previously validated uplex criteria. 
Results: The study group included 26 men and 15 women with a mean age of 65 years, 
who were observed for a mean interval of 34 months. Endovascular stents were placed in 
12 of the 52 arteries. The initial post-PTRA renal artery stenosis classification (based on 
arteriography or duplex scan) was normal in 23, <60% in 19, and ->60% in 10. The 
cumulative incidence of restenosis from normal to ->60% was 13% at I year and 19% at 2 
years. The cumulative incidence of restenosis from <60% to ->60% was 44% at I year and 
55% at 2 years. The cumulative incidence of progression from ->60% to occlusion was 10% 
at 2 years. Although 83% of the 12 stented arteries and only 33% of the 40 nonstented 
arteries were normal immediately after PTRA, after 1 year the stented renal arteries 
showed a 44% restenosis rate, whereas the nonstented renal arteries showed a 18% 
restenosis rate (p = 0.087). 
Conclusions: Restenosis after PTRA for atherosderotic disease is relatively common and 
correlates with the initial anatomic result. Although PTRA with stent placement yields 
superior immediate technical results, the high early restenosis rate is disturbing. (J Vase 
Surg 1997;25:46-54.) 
In 1978 Grfintzig performed the first percuta- 
neous transluminal renal angioplasty procedure 
(PTRA) in a patient with atherosclerotic renovascu- 
lar hypertension} Despite the wide application of 
this technique over the past two decades, there is a 
From the Division of Vascular Surgery and the Department of 
Radiology, University of Washington, and Seattle Veterans Af- 
fairs Medical Center. 
Supported inpart by NIH Grant 1 R01 DK48088-01A1. 
Presented at the Fiftieth Annual Meeting of The Society for 
Vascular Surgery, Chicago, Ill., June 11-12, 1996. 
Reprint requests: R. E. Zierler, MD, Department of Surgery, 
University of Washington, Box 356410, Seattle, WA 98195- 
6410. 
Copyright © 1997 by The Society for Vascular Surgery and Inter- 
national Society for Cardiovascular Surgery, North American 
Chapter. 
0741-5214/97/$5.00 + 0 24/6/77031 
46 
paucity of  objective data on both the short-term and 
long-term results of this procedure. The lack of doc- 
umentation of the anatomic outcome of PTRA is due 
primarily to the reluctance of most clinicians to per- 
form repeat arteriography. In studies that assessed 
the results of  PTRA with arteriography there is typi- 
cally only one post-procedure study, and the average 
follow-up is seldom beyond 12 months. 2 
In several of the large PTRA follow-up studies, 
benefit was measured in terms of clinical rather than 
anatomic results. 3-6 Success or failure is usually based 
on the blood pressure response or some index of 
renal function. The reported blood pressure response 
varies widely as a result of individual study definitions 
of "improvement. "7 One study suggested reporting 
"cure" rates only because spontaneous blood pres- 
sure "improvement" was seen in control patients 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 1 Tullis et al. 47 
without renovascular disease or intervention, s To 
date there have been no large prospective studies that 
correlated long-term serial anatomic and clinical re- 
sults after PTRA. 
Duplex ultrasonography is a noninvasive tech- 
nique with proven validity in the diagnosis of reno- 
vascular disease. 9-13 This method can be used for 
follow-up purposes to document the natural history 
of atherosclerotic renal artery stenosis and the results 
of interventions. 14-18 Duplex ultrasonographic studies 
have provided more complete information regarding 
renal artery disease progression than previous arterio- 
graphic natural history studies because of the feasibility 
of more frequent evaluations? 9,2° The purpose of 
this report was to evaluate by serial duplex ultrasono- 
graphic scans the anatomic results after PTRA for the 
treatment of  atherosclerotic renal artery disease. 
METHODS 
We reviewed the records of patients who under- 
went PTRA and had at least 6 months of follow-up in 
one of two University of  Washington-affiliated non- 
invasive vascular laboratories between November 
1987 and April 1995. All renal arteries had stenosis 
of >60% diameter eduction before PTRA. The 
PTRA procedures were performed at the University 
of Washington Medical Center, the Seattle Veterans 
Affairs Medical Center, and hospitals affiliated with 
the Group Health Cooperative in Seattle. Patients 
were studied with serial duplex ultrasound examina- 
tions after PTRA at the University of Washington or 
the Seattle Veterans Affairs Medical Center noninva- 
sire vascular laboratories. 
The technique of  renal artery duplex scanning has 
been previously reported. 9-1a,~4 All examinations 
were performed with ATL Uttramark 4, 9, or HDI  
duplex ultrasound systems (Advanced Technology 
Laboratories, Bothell, Wash.). Briefly, patients were 
examined after overnight fasting with either a 2.25 or 
3.2 MHz phased array, 3.4 MHz curved linear, or a 3 
MHz mechanical sector transducer. The abdominal 
aorta was evaluated to determine if there was aneu- 
rysmal or occlusive disease, and then the aortic peak 
systolic velocity (PSV) was measured at or above the 
level of  the superior mesenteric artery. Using a mid- 
line approach, the renal arteries were identified with 
the aorta in transverse view, and velocities were re- 
corded along the entire length of  the renal arteries 
with special attention focused at any areas of  in- 
creased velocity or turbulence. The distal renal arter- 
ies, as well as hilar and parenchymal flow, were eval- 
uated via a lateral decubitus or posterior approach if 
they were difficult to locate in the transabdominal 
Table I. Criteria for the classification of 
renal artery disease by ultrasonic 
duplex scanning 
Renal artery 
diameter reduction Renal artery PSV RAR 
Normal (0%) <180 cm/sec <3.5 
<60% ->180 cm/sec <3.5 
->60% ->180 cm/sec ~3.5 
Occlusion (100% ) No signal - -  
PSV, Peak systolic velocity; RAR, renal-aortic ratio (renal PSV/  
aortic PSV). 
views. The angle of the Doppler ultrasound beam 
was 60 degrees or less for all velocity measurements. 
The degree of renal artery stenosis after PTRA 
was classified according to previously validated crite- 
ria based on the renal artery PSV and the renal-aortic 
ratio (RAR). The RAR is defined as the PSV in the 
renal artery divided by the aortic PSV. n On the basis 
of these measurements, he degree of narrowing of 
the renal artery can be classified into one of  four 
categories: 1) normal; 2) <60% stenosis; 3) ->60% 
stenosis; or 4) occluded (Table I). The initial post- 
PTRA renal artery stenosis classification was deter- 
mined by duplex ultrasound if an immediate post- 
procedure study was obtained; otherwise the initial 
result was determined angiographically. Restenosis was 
defined as a change from either the normal or <60% 
stenosis categories to the ->60% stenosis category by 
serial duplex examinations. Renal arteries in the ->60% 
stenosis category could only progress to occlusion. 
In addition to serial duplex examinations, clinical 
information regarding hypertension (HTN) (blood 
pressures and number of antihypertensive medica- 
tions) and renal insufficiency (RI) (serum creatinine) 
was obtained when available. To compare clinical 
and anatomic outcome without the confounding ef- 
fect ofcontralateral renal artery disease, HTN and RI 
responses were only evaluated in patients with a pri- 
mary unilateral PTRA and contralateral renal artery 
disease of <60% stenosis or patients with a solitary 
kidney who underwent PTRA. This analysis was 
based on blood pressure before PTRA and at the last 
follow-up visit, number of  antihypertensive medica- 
tions, and serum creatinine level. Post-PTRA HTN 
response was classified according to a modification of 
the Cooperative Study of Renovascular Hyperten- 
sion recommendations. 21 Patients with HTN were 
classified into one of three categories after PTRA: 
"Cure," diastolic blood pressure (DBP) less than 90 
mm Hg and no hypertensive medications; "Im- 
proved," DBP less than 90 mm Hg and a decrease in 
JOURNAL OF VASCULAR SURGERY 
48 Tull is et al. January 1997 
% 
RESTENOSIS  
or 
PROGRESSION 
100 
90 
80 
70 
60 
50 
40 
20 
10 
0 
0 3 6 12 
T 
I I I 
24 
MONTHS 
36 48 
n = 52 52 47 42 26 17 14 
Fig. 1. Kaplan-Meier curve of overall cummulative post-PTRA restenosis or progression rate. 
n, number of renal arteries entering each interval. 
the number of medications or DBP 90 to 110 mm 
Hg (->15% decrease) and no change or a decrease in 
medications; or "Failure," all other cases. Patients 
were evaluated for RI response if their pre-PTRA 
serum creatinine level was 1.5 mg/d l  or more. Post- 
PTRA RI response was classified into one of the follow- 
ing three categories: "Improved," decrease in serum 
creatinine level (CR) of 20% or more; "No change," 
CR + 19%; "Worse," increase in CRof20% or more. 
Data were analyzed by the SPSS statistical pack- 
age (Version 6.1, SPSS, Inc., Chicago). Estimates for 
the cumulative incidence of renal artery restenosis 
and progression to occlusion were calculated by 
Kaplan-Meier life-table analysis. Because of possible 
dependence of disease progression between the left 
and right renal arteries from the same individual, 
standard statistical software could not be used to 
calculate standard errors or test for group differences. 
The jackknife method 22 was used as an alternative for 
computing standard errors. Standard errors com- 
puted in this way were then used to calculate a 
two-tailed Z statistic yielding the p values reported. 
Pre- and post-PTRA blood pressure and serum cre- 
atinine comparisons were done with Student's t test 
for paired data. 
RESULTS 
The study group included 41 patients who un- 
derwent 52 primary PTRA procedures. There were 
26 men and 15 women with a mean age of 65 years, 
who were followed for a mean interval of  34 months, 
with a maximum of 65 months. The average number 
of duplex examinations per renal artery was five, with 
a maximum of  10 examinations. Palmaz balloon- 
expandable stents (Johnson & Johnson, New Bruns- 
wick, N.J.) were placed in 12 of the 52 arteries. 
Ostial lesions constituted 56% of the renal artery 
stenoses (92% of the stented arteries and 45% of the 
nonstented arteries). Patient risk factors were as fol- 
lows: 17% were diabetic, 61% were smokers, 49% had 
a history of coronary artery disease, 61% had a history 
of peripheral vascular disease, and 37% had a history 
of  cerebral vascular disease. 
One way to stratify PTRA results is to assess the 
development of restenosis on the basis of the initial 
post-PTRA anatomic result. The initial post-PTRA 
renal artery stenosis classification was normal in 23, 
<60% stenosis in 19, and ->60% stenosis in 10. The 
overall incidence of restenosis or progression (nor- 
mal or <60% stenosis to ->60% stenosis, and ---60% 
stenosis to occlusion) was 24% at 1 year, 31% at 2 
years, 34% at 3 years, and 39% at 4 years (Fig. 1). The 
cumulative incidence of  restenosis from normal to 
->60% was 13% at 1 year and 19% at 2 years. The 
cumulative incidence ofrestenosis from <60% steno- 
sis to ->60% stenosis was 44% at 1 year and 55% at 2 
years. This difference in restenosis (normal vs <60% 
stenosis) after 2 years was highly significant (p = 0.009) 
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Fig. 2. Kaplan-Meier curve ofrestenosis rate based on initial post-PTRA duplex classification: 
<60% stenosis vs normal. Interrupted line indicates tandard error greater than 10%. n, number 
of renal arteries entering each interval. The difference in restenosis between groups after 24 
months was highly significant (p = 0.009). 
(Fig. 2). The cumulative incidence of  progression 
from ->60% stenosis to occlusion was 10% at 2 years. 
Another way to stratify the data is to evaluate the 
development ofrestenosis on the basis ofstent place- 
ment after PTRA. Forty renal arteries had conven- 
tional PTRA (mean follow-up, 33 months) and 12 
renal arteries had stents placed (mean follow-up, 15 
months). Ten of  the 12 (83%) stented arteries and 13 
of  the 40 (33%) nonstented arteries were classified as 
normal by angiographic or duplex criteria after 
PTRA. However, after 1 year, the stented renal arter- 
ies showed a 44% restenosis rate, whereas the non- 
stented renal arteries howed an 18% restenosis rate. 
This difference in restenosis rates approached statisti- 
cal significance (p = 0.087) (Fig. 3). 
There was sufficient data to evaluate the blood 
pressure response in 18 patients with a mean fol- 
low-up of 28 months. After PTRA two patients 
(11%) were cured and six (33%) were improved. 
There was a significant decrease before and after 
PTRA in systolic (183 _+ 41 vs 153 -+ 31 mm Hg; 
p = 0.004) and diastolic (91 - 19 vs 77 +- 10 mm 
Hg; p = 0.020) blood pressures, but no change in 
the number of  HTN medications (2.3 - 0.9 vs 2.2 _+ 
1.2; p = 0.826) for the entire hypertensive group. 
Ten patients with a mean follow-up of  31 months 
had KI by the criteria previously mentioned. These 
10 patients were a subset of the 18 HTN patients. In 
five of the 10 (50%), RI was a coindication for PTRA. 
After PTRA five patients (50%) were improved and 
four (40%) had no change in RI. However, there was 
no significant change between the pre- and post- 
PTRA CR (2.10 _+ 0.62 vs 2.03 - 0.89 mg/dl ;  p -- 
0.777) for the entire RI group. 
Although the two HTN "cured" patients had 
normal restflts on duplex examinations at the last 
visit, there was poor correlation with the anatomic 
result in the "improved" and "failure" categories. 
Five of the six (83%) improved patients had a final 
duplex stenosis -60%, and six of the 10 failures 
(60%) had a final duplex diagnosis of normal. There 
appeared to be better anatomic correlation in pa- 
tients with improved or stabilized renal function 
compared with those patients with a positive hyper- 
tensive response. Eight of  the nine patients (89%) 
with improved or no change in renal function had a 
final duplex diagnosis of either normal or <60% 
stenosis (Table II). 
DISCUSSION 
It is important o point out that the population 
for this study was accumulated by reviewing the 
records of two vascular laboratories over the period 
of time indicated. One of  the referral sources was a 
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Fig. 3. Kaplan-Meier curve of post-PTRA restenosis rate: stent vs no stent. Interrupted line 
indicates tandard error greater than 10%. n, number of renal arteries entering each interval. The 
difference in restenosis between groups after 12 months approached statistical significance (p = 
0.087). 
large HMO contracting with several hospitals that 
were unable to provide complete data on the number 
of PTRA procedures performed over the study pe- 
riod. Therefore, the total number of  PTRA proce- 
dures done at all sites during the study period could 
not be determined. For this reason it is not possible 
to interpret he data in terms of overall technical 
success or any other parameters dependent on a con- 
secutive series of cases. Also of note is that renal 
artery stenting was not performed uring the study 
interval before 1992. Of  the 10 renal arteries with 
post-PTRA residual stenoses of ->60%, eight of the 
procedures (80%) were performed before 1992. In 
addition, those patients with renal artery lesions that 
could not be crossed with a guide wire and those 
with immediate post-PTRA occlusions were not in- 
cluded in this study. The intent of this study was to 
serially observe atherosclerotic PTRA-treated arteries 
for anatomic hanges. Complete, consecutive data is 
obviously best obtained in a prospective fashion. We 
are currently collecting such data from patients who 
undergo PTRA while being followed prospectively as
part of a large natural history study of atherosclerotic 
renovascular disease at our institution. ~,16 In fact, 
23 of the 41 patients (56%) (representing 31 of the 
52 treated arteries), in the current report were pro- 
spectively studied as part of this natural history 
project. The protocol for duplex scanning in the 
prospective natural history study was yearly examina- 
tions if both renal arteries were normal or had a 
<60% stenosis and every 6 months for patients with 
at least one renal artery showing a ->60% stenosis. 
There was no established protocol for the retrospec- 
tive patients in the study. The average interval for 
duplex examinations in this group was 8.6 months 
(maximum, 40 months). It should be noted that 
there was no statistical difference in the incidence of 
restenosis or disease progression between the arteries 
studied prospectively and those analyzed retrospec- 
tively (prospective 31 arteries, 39%, retrospective 21 
arteries, 24%; p = 0.259). 
A possible limitation in this study is the applica- 
tion of established uplex criteria to stented renal 
arteries. To our knowledge, there have been no stud- 
ies that validated the use of duplex ultrasonographic 
scans for classifying renal artery stenosis after PTRA 
with or without stent placement. However, in our 
experience, stents do not interfere with renal artery 
ultrasound examinations and are usually well visual- 
ized on B-mode imaging. Anecdotally, we have 
found that when duplex scanning has detected a
stenosis in a renal artery that has been treated by 
PTRA and stenting, it is subsequently confirmed 
with contrast angiography. Therefore, we feel confi- 
dent in applying the current duplex criteria to 
stented renal arteries. 
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Table II. Clinical versus anatomic outcome 
HTN 
(n= 18) 
Final duplex 
catagory Cure Improved Failure 
R I  
(n= lo) 
Improved No change Worse 
Normal 2 1 6 4 3 1 
<60% stenosis 1 1 
-->60% stenosis 5 3 1 
A central finding in this study is the relationship 
of the initial post-PTRA anatomic result o the reste- 
nosis rate. For those lesions which were classified as 
<60% stenosis immediately after PTRA, the rate of 
restenosis after 2 years was 55% versus those arteries 
which were normal after PTRA, with a rate of 19%. 
Several investigators have reported an increase in the 
restenosis rate in association with a post-PTRA resid- 
ual stenosis >30%. 6,23 Because the technical result of 
PTRA seems to influence the ultimate restenosis rate, 
the criteria for reporting "technical success" should 
ideally reflect this fact. The definition of immediate 
technical success, based on the degree ofpost-PTRA 
residual stenosis, varies among reports; it ranges from 
30% 3,24 tO 50% 4,5 post-angioplasty residual stenosis, 
or it isn't reported. 6 One study defined "partial" 
technical success as a residual stenosis of "more than 
50%, but less than or equal to 70%. "4 
Martin et al.2 recently reviewed 10 studies with 
follow-up arteriography to better determine the inci- 
dence of restenosis after PTRA or stenting for ath- 
erosclerotic renovascular disease in 518 patients. Re- 
stenosis was reported as a >50% diameter-reducing 
lesion in the six studies that gave a definition. Only 
one study reported amean follow-up in excess of 12 
months, and technical failures were excluded from 
analysis or not mentioned in eight of the studies. 
With those limitations, the overall incidence ofreste- 
nosis was 30%. In the one prospective study with 
serial angiographic follow-up comparing PTRA to 
surgery, the restenosis rate by life-table analysis after 
primary PTRA was 34% after 2 years. 25 The 4-year 
restenosis or progression rate was 39% for the entire 
group of patients in the present study. 
Atherosclerotic renovascnlar lesions are often dif- 
ficult to dilate by conventional percutaneous angio- 
plasty techniques. This is especially true with lesions 
at the renal artery ostium. 23 Renal artery stenting is 
now frequently used in the event of a poor angio- 
graphic result with conventional PTRA, and multiple 
investigators have reported excellent technical results 
after PTRA with these often very difficult lesions.26-28 
The same is true in the patients who had stents 
placed in this study. Despite the fact that 92% of the 
stented renal arteries had ostial lesions, 83% were 
normal by angiographic or duplex criteria after 
PTRA. An emerging concern related to stent use is 
the development ofrestenosis. The post-PTRA stent 
restenosis rate varies among reports from 12% to 
39%, with the mean follow-up ranging from less than 
6 months to 29 months. 26,27,29,3° Our results howed 
that 44% of the stented renal arteries developed reste- 
nosis by 1 year of follow-up. This is in close agree- 
ment with the multicenter report by Rees et  al,29 
which showed a 39% restenosis rate in patients who 
underwent follow-up arteriography at a mean of 7 
months. The authors stated that in their series and 
other reports "angiographic restenosis was often 'si- 
lent' (i.e. unaccompanied by a relapse of hyperten- 
sion), so that clinical data alone, without follow-up 
arteriography, could not predict the prevalence of 
anatomic restenosis. ''29 This is an important point 
when attempting to correlate a PTRA intervention 
with a clinical response. Finally, it is difficult to sort 
out whether estenosis after stent placement is caused 
by the stent itself or the nature of ostial disease. 
There also appear to be specific risk factors 
emerging in relation to renal artery stent restenosis. 
As a continuation of their original work, Rees et al. 
recently reported statistically significant factors asso- 
ciated with the development of post-PTRA stent 
restenosis in 263 patients. They found that male 
gender and stent dilatation to 6 mm or greater were 
associated with lower rates of restenosis? 1 Although 
there were only 12 stents placed in the present study, 
it is interesting that four of the five stents that re- 
stenosed were in female patients, and the only male 
patient with restenosis had two stents placed, one 
was dilated to 6 mm and the other to 5 mm. 
Because it is much easier to obtain clinical fol- 
low-up information than to subject patients to fol- 
low-up arteriography, the majority of mid- and long- 
term PTRA results are reported in terms of 
hypertensive or renal function responses. Hyperten- 
sive response is generally reported, as it was in this 
study, in terms of"cure" and "improvement" results, 
which are combined to form a "total benefit" cate- 
gory. In a meta-analysis of 653 patients after PTRA 
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for atherosclerotic disease, 13% were cured and 52% 
were improved, for a 65% total benefit. 2 Of  note, the 
majority of the studies in that analysis excluded tech- 
nical failures and some included redilatations, both 
of which would improve the overall results. In an 
effort to eliminate potential contralateral lddney ef- 
fects, we limited our clinical analysis to unilateral 
disease and found an 11% cure rate and a 33% im- 
provement, for a total benefit of 44% after PTRA. 
One report challenged the validity of an "improve- 
ment" category because the percentage of control 
patients without renovascular hypertension who 
showed spontaneous improvement and those who 
were improved after PTRA was statistically equal. 
The investigators questioned the consequences of 
factors uch as regression to the mean, placebo effect, 
treatment changes, or altered compliance, which are 
routinely controlled for in studies of hypertension 
but not in any of  the PTRA studies. 8 Because the 
"cure" category is the most objective clinical end- 
point (blood pressure less than 140/90 and no hy- 
pertensive medications), it may be the only strictly 
valid measure available to compare interventions. 
Although the intent of this report was to serially 
document post-PTRA anatomic hanges, it was in- 
teresting to look at the correlation between the final 
anatomic and clinical results. There was a poor cor- 
relation between the blood pressure response and 
final anatomic classification. Although both cured 
patients had normal results on duplex examination, 
five out of six (83%) of the improved patients had a 
->60% stenosis, and six of the 10 (60%) hypertensive 
failures had normal post-PTRA arteries. This is not a 
unique finding. In a recent report, 42 of  71 patients 
with hypertension (59%) were cured or improved 
after a technically unsuccessful PTRA (> 50% residual 
stenosis). The investigators found no statistically sig- 
nificant relationship between technical and clinical 
success. 5 Perhaps there is a subset of patients in 
whom a marginal post-PTRA improvement is all that 
is needed to convert he lesion into a non-hemody- 
namically significant stenosis. There was better corre- 
lation between renal function and the final anatomic 
classification i  this study, where 80% of the arteries 
in patients who were in the improved or unchanged 
categories had a normal or <60% stenosis classifica- 
tion. This result could also partially reflect he defini- 
tions used to classify the renal insufficiency response 
to PTRA. 
The questions raised above are not new, and it is 
interesting that they are still central to the contro- 
versy regarding the utility of PTRA for the treatment 
of atherosclerotic renovascular disease nearly 20 
years after the procedure was first reported. Ramsay 
and Waller, 7 in their review of 10 large PTRA series, 
concluded that angioplasty has been evaluated in a 
haphazard and unscientific way, and that if similar 
data were used to support he efficacy of  a new drug, 
no regulatory body would find them acceptable. A 
recent editorial by Porter 32 echoes the same concern, 
calling for interventionalists (and surgeons) to pro- 
duce cohort studies with proper randomization and 
controls to establish scientific redibility for endovas- 
cular procedures. We believe that serial anatomic 
data is a critical element in this evaluation process. 
CONCLUSION 
Duplex ultrasonography is a proven technology 
for the diagnosis and follow-up of renovascular dis- 
ease and is the preferred method for serial evaluation 
of post-PTRA anatomic results. With this approach 
we have demonstrated that restenosis after PTRA for 
atherosclerotic disease is relatively common and cor- 
relates with the initial anatomic result. Although 
PTRA with stent placement yields superior immedi- 
ate technical results, the high early restenosis rate 
highlights the need for a better understanding of the 
renal artery response to injury. The relationship be- 
tween the anatomic and clinical results of PTRA for 
atherosclerotic renovascular disease remains unclear. 
Although the clinical outcome is the ultimate end- 
point of any intervention, the anatomic results of 
PTRA must be considered when comparing this ap- 
proach with surgical treatment for renal artery ath- 
erosclerosis. 
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D ISCUSSION 
Dr. Richard H .  Dean (Winston-Salem, N.C.). Like 
everyone here, I am deeply appreciative of  the work that 
the entire Seattle group has done over the past several years 
with Doppler ultrasound, duplex sonography, and now 
with their prospective studies relative to renal vascular 
disease. I must say that this report fits well with what I 
wanted to hear, and thereby I am quite pleased with the 
presentation; namely, that PTRA, or even PTRA with 
stents, does not hold up as well as surgery performed for 
this indication. 
In this regard, however, I have two points that I would 
like to make and one question I would like to ask. My first 
point is to remind the audience that although some of 
today's reported cases came from the authors' prospective 
study of  changes in the renal artery over time, which is 
being conducted at the University of  Washington, the 
report is, in essence, a retrospective r view of a selected or, 
if you will, biased population. Spedfically, these patients 
were recruited from several sites at which PTRA had been 
performed and then studied in their laboratories; thereby 
the total number of  PTRA procedures performed at those 
respective sites are not included in the study. Therefore, we 
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do not know the denominator of how many restenoses 
occurred out of a total group of PTRA patients with or 
without stents. If  the total group were 41, then this is very, 
very valuable data. If the total group of angioplasty patients 
was 421, then the recurrence rate is quite low. So my 
question would be, do you have such data? 
My second comment relates to the use of the aortic-to- 
renal peak systolic velocity ratio as an important compo- 
nent of determining severity of stenosis. I must admit that 
this comment required my education by Kim Hansen--no 
small task. In our center we have not continued to use the 
peak systolic velocity ratio of the aorta to determine 
thereby a ratio, but have relied most recently solely on the 
peak systolic velocity of the renal artery flow. Clearly, we 
have an older group of people, and our problem with aortic 
peak systolic velocity may be peculiar to our older age 
group in that we have found several instances on serial 
follow-up out of our total group of 1500 studies in which 
the peak systolic aortic velocity varied significantly from 
one examination to another elating to changes in antihy- 
pertensive medications affecting cardiac performance and 
changes in cardiac performance itself. 
Although we have not reported this specific finding 
from our experience, this variation can affect he classifi- 
cation of movement from <60% to >60% stenoses by 
affecting aortic peak systolic velocity alone. So my ques- 
tion is, how many of those patients that moved from a 
<60% stenosis to a >60% stenosis actually moved there 
by a change in the peak aortic systolic velocity rather 
than a change in the peak renal artery systolic velocity. 
Clearly, if it was significant, then these may be aberrant 
rates of progression based on this technical aspect of the 
study. 
Again, I deeply appreciate the opportunity to discuss 
this presentation, and I look forward to reading further 
publications from the Seattle group as they prospectively 
observe a progressively larger group of people who have 
renal artery disease. 
Dr. Michael J. Tullis. Regarding your first comment 
about our patient population, we would echo your con- 
cerns in interpreting the results of this retrospective non- 
consecutive series of patients in a general manner. How- 
ever, we believe that this study was unique with respect to 
the mean patient follow-up period, which was nearly 3 
years, and also the intensity with which we interrogated the 
renal arteries. This information is clearly lacldng in the 
interventional radiology literature. As you alluded to, we 
are currently studying these patients in a prospective fash- 
ion. 
Your second comment was regarding the use of the 
renal-to-aortic ratio. We are very comfortable with the use 
of this ratio and have validated it against arteriography. 
However, we are also aware that when the aortic peak 
systolic velocity is low, the renal-aortic ratio can be falsely 
elevated because the aortic velocity is in the denominator 
of the ratio. In patients who have low aortic velocities and a 
borderline 60% stenosis, we take this possible elevation 
into account and would classify such lesions as <60% 
stenosis. We do not find this to be much of a problem with 
our patient population. Perhaps, as you suggested, we see a 
slightly different group of patients than you do at your 
institution. 
Dr. David C. Brewster (Boston, Mass.). Although 
your data do not  really include a large number ofstents, I 
rise simply to reemphasize some of what I believe are 
potentially concerning implications of your findings. I 
think we are all well aware of the increasing interest and 
enthusiasm for stenting of renal artery lesions. These are 
largely orificial and, indeed, stents have certain logic to 
them to improve early results by preventing elastic recoil 
and other factors that may lead to inadequate initial recan- 
alization. 
However, as one thinks about it, and similar to experi- 
ence with iliac PTA, it is really quite hard to understand 
how stents will preclude the two major causes of late 
failure, that is, intimal hyperplasia or recurrent atheroscle- 
rotic stenosis, and indeed your data seem to suggest hat 
this skepticism should be underscored. 
It is commonly believed that the use of stenting when 
performing PTA as an initial therapy may be reasonable 
because the use ofstents usually does not preclude surgery. 
But I would simply point out that in the renal area, this 
may not be the case. Stents, particularly if they are project- 
ing into the renal artery for any distance, may make subse- 
quent surgical repair by bypass grafting quite difficult and, 
of course, preclude ndarterectomy that many centers and 
groups are increasingly using recently. So I think that the 
implications of your stent data are quite important. 
Dr. TuUis. Thank you for your comments, Dr. Brew- 
ster. 
Dr. Sven-Erik Bergentz (Malmo, Sweden). We have 
previously reported, in a series presented for this Society, 
our results in patients who were undergoing PTA without 
stenting to treat atherosclerotic renal artery stenosis. We 
found the same high incidence of recurrences that you have 
demonstrated. We also found, however, that if we observe 
the patients closely, and redilatc their renal arteries as soon 
as they show signs of restenosis, we can improve our 
long-term results considerably. As a matter of fact, the 
results then become almost identical to the results we get 
in an operated series that was prospectively randomized. 
My question is, therefore, have you redilated the renal 
arteries when you found recurrences, and in that case, what 
were your results? 
Dr. Tullis. In the group of patients we studied, there 
was a small subset of individuals who did undergo redilata- 
tion procedures, but because we were looldng at the results 
of primary PTRA, redilation was considered an endpoint in 
the study. Redilation after PTRA is certainly not uncom- 
mon at our institution; however, we do not know what 
happens to these lesions at this time. We are currently 
collecting this information in a prospective manner. 
